Hudson Canyon Investment Counselors LLC raised its stake in shares of Allergan PLC (NYSE:AGN) by 14.8% during the second quarter, Holdings Channel reports. The firm owned 5,662 shares of the company’s stock after buying an additional 729 shares during the period. Hudson Canyon Investment Counselors LLC’s holdings in Allergan PLC were worth $1,308,000 at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in AGN. Barnett & Company Inc. purchased a new stake in shares of Allergan PLC during the first quarter worth about $111,000. Ropes Wealth Advisors LLC raised its stake in shares of Allergan PLC by 13.2% in the first quarter. Ropes Wealth Advisors LLC now owns 497 shares of the company’s stock worth $133,000 after buying an additional 58 shares in the last quarter. Livingston Group Asset Management CO operating as Southport Capital Management purchased a new stake in shares of Allergan PLC during the second quarter worth about $125,000. Trust Co. of Vermont raised its stake in shares of Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock worth $126,000 after buying an additional 89 shares in the last quarter. Finally, Integrated Investment Consultants LLC raised its stake in shares of Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock worth $137,000 after buying an additional 154 shares in the last quarter. Institutional investors and hedge funds own 85.19% of the company’s stock.
Shares of Allergan PLC (NYSE:AGN) traded up 1.06% during mid-day trading on Monday, hitting $232.75. The company had a trading volume of 3,154,753 shares. Allergan PLC has a one year low of $195.50 and a one year high of $322.68. The company’s 50-day moving average is $242.33 and its 200 day moving average is $240.70. The company has a market capitalization of $92.16 billion, a PE ratio of 22.16 and a beta of 0.81.
Allergan PLC (NYSE:AGN) last announced its quarterly earnings results on Monday, August 8th. The company reported $3.35 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.34 by $0.01. The company earned $3.68 billion during the quarter, compared to analysts’ expectations of $4.10 billion. Allergan PLC had a return on equity of 7.67% and a net margin of 28.06%. The firm’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same period in the previous year, the business earned $4.41 earnings per share. On average, equities research analysts forecast that Allergan PLC will post $14.00 EPS for the current fiscal year.
A number of equities research analysts recently issued reports on AGN shares. Sanford C. Bernstein reissued an “outperform” rating and issued a $335.00 target price on shares of Allergan PLC in a research report on Thursday, June 9th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Allergan PLC in a research report on Friday, June 10th. Vetr raised Allergan PLC from a “buy” rating to a “strong-buy” rating and set a $272.91 price target on the stock in a research report on Monday, June 13th. Piper Jaffray Cos. reaffirmed a “hold” rating and set a $236.00 price target on shares of Allergan PLC in a research report on Saturday, June 18th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Allergan PLC in a research report on Saturday, June 25th. Six equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $300.64.
About Allergan PLC
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC (NYSE:AGN).
Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.